as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,580.5
Change
-51.9 (-3.18%)
Open
₹1,632.4
Prev. Close
₹1,632.4
Day High
₹1,639.3
Day Low
₹1,570.0
Volume Analysis
Traded
594
Delivered
459
Delivery %
77.27%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Promoter holding is rising
Weaknesses (1)
- •Low return on equity (8.44%)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,692.5 | ₹1,665.9 | ₹1,623.2 | ₹1,596.6 | ₹1,553.9 | ₹1,527.3 | ₹1,484.6 |
| Fibonacci | ₹1,665.9 | ₹1,639.43 | ₹1,623.07 | ₹1,596.6 | ₹1,570.13 | ₹1,553.77 | ₹1,527.3 |
| Camarilla | ₹1,599.56 | ₹1,593.21 | ₹1,586.85 | ₹1,596.6 | ₹1,574.15 | ₹1,567.8 | ₹1,561.44 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+20.65%
1 Week
-0.85%
1 Month
-0.21%
3 Months
+7.88%
6 Months
-4.72%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹592.22
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
7.94%
Net margin 3.29% × asset turnover 1.2x × equity multiplier 2.01x
Company Overview
Sector
Healthcare
Market Cap
₹494 Cr
P/E (TTM)
38.1
ROE
8.44%
Book Value
₹725.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.
TopFund Analysis
Haleos Labs Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 52/100. The strongest factor is Financial Strength (81/100), while Institutional Ownership (30/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (8.44%).
TopFund Score — Fundamentals Quality
52/100 — AverageData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −The company has delivered a poor sales growth of 4.68% over past five years.
- −Company has a low return on equity of 8.23% over last 3 years.
- −Company might be capitalizing the interest cost
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Enclosed - Newspaper advertisement for Q2F27 (results)
Haleos Labs withholds FY26 dividend for shareholders with incomplete KYC or incorrect bank details.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 69 | 72 | 90 | 93 | 78 | 85 | 89 | 83 | 81 | 95 | 75 | 73 | 91 |
| Expenses + | 61 | 63 | 79 | 76 | 70 | 72 | 82 | 71 | 68 | 81 | 71 | 64 | 83 |
| Operating Profit | 8 | 9 | 11 | 16 | 9 | 13 | 7 | 12 | 14 | 14 | 4 | 9 | 8 |
| OPM % | 11.45% | 12.91% | 12.62% | 17.59% | 10.92% | 15.07% | 8.33% | 14.19% | 16.69% | 14.82% | 5.54% | 12.5% | 9.1% |
| Other Income + | 0 | 1 | 2 | 0 | 2 | 0 | 2 | 1 | 0 | 0 | 2 | 0 | 0 |
| Interest | 3 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Profit before tax | 2 | 4 | 7 | 11 | 5 | 7 | 4 | 7 | 8 | 9 | 1 | 3 | 2 |
| Tax % | 126.51% | -8.14% | 8.73% | 33.27% | 29.72% | 29.81% | 11.45% | 37.61% | 24.38% | 24.26% | 62.22% | 46.51% | 12.5% |
| Net Profit + | 0 | 4 | 6 | 7 | 3 | 5 | 3 | 4 | 6 | 7 | 0 | 2 | 2 |
| EPS in Rs | 2 | 14 | 20 | 23 | 15 | 18 | 10 | 14 | 20 | 22 | 1 | 9 | 11 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | -15 | -18 | 41 | 24 | 13 | 17 | -1 | -11 | 4 | 12 | -16 | -12 | 12 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0 | 0 | 218 | 213 | 378 | 261 | 266 | 350 | 316 | 306 | 345 | 334 | 334 |
| Expenses + | 0 | 0 | 189 | 200 | 343 | 235 | 235 | 316 | 287 | 275 | 300 | 289 | 299 |
| Operating Profit | 0 | 0 | 28 | 13 | 35 | 25 | 30 | 35 | 29 | 31 | 45 | 45 | 36 |
| OPM % | — | — | 13.0% | 6.0% | 9.0% | 10.0% | 11.0% | 10.0% | 9.0% | 10.0% | 13.0% | 13.0% | 11.0% |
| Other Income + | 0 | 0 | 2 | 3 | 2 | 2 | 2 | 14 | 5 | 4 | 5 | 2 | 3 |
| Interest | 0 | 0 | 6 | 4 | 6 | 5 | 5 | 6 | 7 | 10 | 9 | 7 | 7 |
| Depreciation | 0 | 0 | 6 | 6 | 6 | 8 | 8 | 10 | 11 | 15 | 15 | 15 | 16 |
| Profit before tax | 0 | 0 | 18 | 6 | 25 | 15 | 20 | 33 | 17 | 10 | 26 | 25 | 15 |
| Tax % | — | — | 30.0% | -2.0% | 30.0% | 31.0% | 31.0% | 23.0% | 31.0% | 36.0% | 28.0% | 29.0% | — |
| Net Profit + | 0 | 0 | 13 | 6 | 18 | 10 | 14 | 25 | 11 | 6 | 19 | 18 | 11 |
| EPS in Rs | — | — | — | 22 | 59 | 34 | 45 | 84 | 38 | 30 | 67 | 57 | 43 |
| Dividend Payout % | — | — | 0.0% | 0.0% | 3.0% | 0.0% | 3.0% | 2.0% | 4.0% | 5.0% | 2.0% | 3.0% | — |
| Sales growth | — | — | — | -2 | — | -31 | 2 | 32 | -10 | -3 | 13 | -3 | -1 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 0 | 0 | 82 | 85 | 103 | 113 | 126 | 149 | 166 | 174 | 194 | 211 | 216 |
| Borrowings + | 0 | 0 | 26 | 27 | 47 | 65 | 65 | 80 | 100 | 101 | 86 | 111 | 135 |
| Other Liabilities + | 0 | 0 | 67 | 61 | 116 | 72 | 108 | 125 | 126 | 114 | 107 | 130 | 146 |
| Total Liabilities | 0 | 0 | 175 | 177 | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 454 | 500 |
| Fixed Assets + | 0 | 0 | 73 | 69 | 118 | 124 | 130 | 142 | 228 | 223 | 232 | 268 | 259 |
| CWIP | 0 | 0 | 0 | 7 | 3 | 16 | 38 | 51 | 1 | 6 | 0 | 10 | 30 |
| Investments | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 0 | 0 | 102 | 95 | 148 | 113 | 134 | 164 | 166 | 162 | 158 | 176 | 210 |
| Total Assets | 0 | 0 | 175 | 177 | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 454 | 500 |
| Equity Capital | 0 | 0 | 0 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 0 | 20 | 8 | 30 | 15 | 35 | -11 | 15 | 24 | 34 | 37 |
| Cash from Investing Activity + | 0 | 0 | -8 | -7 | -44 | -27 | -26 | -7 | -31 | -18 | -15 | -58 |
| Cash from Financing Activity + | 0 | 0 | -12 | -1 | 15 | 12 | -3 | 11 | 17 | -7 | -19 | 21 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 1 | 0 | 6 | -8 | 0 | -1 | 0 | 1 |
| Free Cash Flow | 0 | 0 | 12 | 4 | 6 | -9 | 0 | -53 | -28 | 4 | 19 | -21 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | — | — | 87 | 66 | 105 | 69 | 133 | -10 | 62 | 88 | 94 | 98 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 29.31% | 28.81% | 28.59% | 28.57% | 28.59% | 28.6% | 28.56% | 28.57% | 27.91% | 27.59% | 27.58% | 27.58% |
| Promoters | 70.68% | 71.19% | 71.4% | 71.4% | 71.4% | 71.4% | 71.4% | 71.4% | 71.79% | 72.1% | 72.1% | 72.1% |
| FII | 0.0% | 0.0% | 0.01% | 0.02% | 0.0% | 0.0% | 0.03% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.03% | 0.29% | 0.3% | 0.31% | 0.31% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Haleos Labs Limited (this stock) | 494 | 38.1 | 2.25 | 8.44% |
| Valiant Laboratories Ltd | 570 | 35.2 | 1.72 | -2.55% |
| Medicamen Biotech Limited | 407 | 35.2 | 1.39 | 3.95% |
| Fabtech Technologies Ltd | 609 | 20.5 | 1.39 | 12.0% |
| Rays Of Belief Limited | 615 | 99.3 | 4.03 | 16.1% |
| Qms Medical Allied S Ltd | 336 | 31.3 | 3.23 | 10.4% |
| Lyka Labs Ltd. | 328 | — | 3.39 | -10.2% |
Which Mutual Funds Hold Haleos Labs Limited?
Frequently Asked Questions about Haleos Labs Limited
Haleos Labs Limited (HALEOSLABS) closed at ₹1,580.5 on NSE on 19 November 2026, down 51.9 (3.18%) from the previous close.
Haleos Labs Limited trades on the NSE (National Stock Exchange of India) under the symbol HALEOSLABS.
Haleos Labs Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 38.1.
Haleos Labs Limited has a dividend yield of 0.09%.
Haleos Labs Limited's 52-week high is ₹1,778.0 and its 52-week low is ₹1,091.0.
Haleos Labs Limited has a market capitalisation of ₹494 crore.
Haleos Labs Limited has a TopFund Quality Score of 52/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Haleos Labs Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.